Literature DB >> 23371321

Update in the management of extraintestinal manifestations of inflammatory bowel disease.

Seema A Patil1, Raymond K Cross.   

Abstract

Inflammatory bowel disease, comprised of Crohn's disease and ulcerative colitis, are chronic inflammatory disorders of the gastrointestinal tract. Up to 40 % of patients with inflammatory bowel disease can develop inflammation in other organ systems of the body. These extraintestinal manifestations (EIM) can affect the musculoskeletal, ocular, mucocutaneous, and hepatobiliary systems. Symptoms related to EIM can result in impaired quality of life, and complications of EIM can lead to disfigurement, functional deficits, and even life-threatening organ dysfunction. Some EIM parallel the activity of IBD, and respond to treatment of the underlying disease. Others, however, follow an independent course and require targeted treatment.

Entities:  

Mesh:

Year:  2013        PMID: 23371321     DOI: 10.1007/s11894-013-0314-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  44 in total

Review 1.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

2.  The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.

Authors:  C N Bernstein; J F Blanchard; P Rawsthorne; N Yu
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

3.  Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis.

Authors:  M Kaya; B T Petersen; P Angulo; T H Baron; J C Andrews; C J Gostout; K D Lindor
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

Review 4.  Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.

Authors:  J Braun; X Baraliakos; J Listing; J Sieper
Journal:  Arthritis Rheum       Date:  2005-08

5.  Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.

Authors:  K de Vlam; H Mielants; C Cuvelier; F De Keyser; E M Veys; M De Vos
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

6.  Topical tacrolimus in the management of peristomal pyoderma gangrenosum.

Authors:  C C Lyon; M Stapleton; A J Smith; S Mendelsohn; M H Beck; C E Griffiths
Journal:  J Dermatolog Treat       Date:  2001-03       Impact factor: 3.359

7.  Cholangiocarcinoma complicating primary sclerosing cholangitis.

Authors:  C B Rosen; D M Nagorney; R H Wiesner; R J Coffey; N F LaRusso
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

8.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

Review 9.  Review article: oral ulceration--aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic.

Authors:  E A Field; R B Allan
Journal:  Aliment Pharmacol Ther       Date:  2003-11-15       Impact factor: 8.171

10.  Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes.

Authors:  Timothy R Orchard; C N Chua; Tariq Ahmad; Hung Cheng; Kenneth I Welsh; Derek P Jewell
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682

View more
  6 in total

1.  Evaluation of cardiac function by two-dimensional speckle tracking echocardiography in ulcerative colitis patients.

Authors:  Altug Cincin; Murat Sunbul; Tarık Kivrak; Halil Atas; Ibrahim Sari; Kursat Tigen; Tarik Kani; Hakan Akin; Nese Imeryuz; Yelda Basaran
Journal:  Dig Dis Sci       Date:  2014-07-15       Impact factor: 3.199

2.  Prevalence and characteristics of ophthalmological extra-intestinal manifestations in Chinese patients with inflammatory bowel disease.

Authors:  Ying-Chao Li; Wei-Zhi Li; Chang-Rui Wu; Yun Feng; Li Ren; Chen Mi; Yang Li
Journal:  Int J Ophthalmol       Date:  2016-10-18       Impact factor: 1.779

Review 3.  Gut-lung crosstalk in pulmonary involvement with inflammatory bowel diseases.

Authors:  Hui Wang; Jing-Shi Liu; Shao-Hua Peng; Xi-Yun Deng; De-Mao Zhu; Sara Javidiparsijani; Gui-Rong Wang; Dai-Qiang Li; Long-Xuan Li; Yi-Chun Wang; Jun-Ming Luo
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

Review 4.  Oral manifestation in inflammatory bowel disease: a review.

Authors:  Kamran B Lankarani; Gholam Reza Sivandzadeh; Shima Hassanpour
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

Review 5.  Ophthalmic manifestations in patients with inflammatory bowel disease: A review.

Authors:  Leandro Lopes Troncoso; Ana Luiza Biancardi; Haroldo Vieira de Moraes; Cyrla Zaltman
Journal:  World J Gastroenterol       Date:  2017-08-28       Impact factor: 5.742

Review 6.  Epidemiology of Ocular Manifestations in Autoimmune Disease.

Authors:  Katie Glover; Deepakkumar Mishra; Thakur Raghu Raj Singh
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.